Leptomycin B enhances CDDP-sensitivity via nuclear accumulation of p53 protein in HPV-positive cells

Cancer Science

Volumn 94, Issue 12, 2003, Pages 1099-1103

  Naniwa, Jun ^a   Kigawa, Junzo ^a   Akeshima, Ryoji ^a   Kanamori, Yasunobu ^a   Itamochi, Hiroaki ^a   Oishi, Tetsuro ^a   Iba, Takahiro ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; LEPTOMYCIN B; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; VIRUS DNA CELL DNA INTERACTION; WART VIRUS; WILD TYPE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL NUCLEUS; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FATTY ACIDS, UNSATURATED; FEMALE; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; PAPILLOMAVIRUS INFECTIONS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0345768470     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01406.x     Document Type: Article

References (25)

1. FIGO. Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 1991; 36 (Suppl): 38-39.
2. Panici PB, Greggi S, Scambia G, Ragusa G, Baiocchi G, Battaglia F, Coronettta F, Mancuso S. High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: preliminary report. Gynecol Oncol 1991; 41: 212-6.
3. Sardi J, Sananes C, Giaroli A, Maya G, Paola GD. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol 1990; 38: 486-93.
4. Kigawa J, Minagawa Y, Ishihara H, Itamochi H, Kanamori Y, Terakawa N. The role of neoadjuvant intraarterial infusion chemotherapy with cisplatin and bleomycin for locally advanced cervical cancer. Am J Clin Oncol 1996; 19: 255-9.
5. Minagawa Y, Kigawa J, Irie T, Okada M, Kanamori Y, Terakawa N. Radical surgery following neoadjuvant chemotherapy for patients with stage IIIB cervical cancer. Ann Surg Oncol 1998; 5: 539-43.
6. Andrews PA, Velury S, Mann SC, Howell SB. Cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988; 48: 68-73.
7. Lautier D, Canitrot Y, Deeley RG, Cole SP. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 1996; 52: 967-77.
8. Kigawa J, Minagawa Y, Cheng X, Terakawa N. Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 1998; 4: 1737-41.
9. Righetti SC, Della TG, Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56: 689-93.
10. Minagawa Y, Kigawa J, Itamochi H, Kanamori Y, Shimada M, Takahashi M, Terakawa N. Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways. Jpn J Cancer Res 1999; 90: 1373-9.
11. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993; 74: 777-9.
12. Takahashi M, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Kamazawa S, Sato S, Akeshima R, Terakawa N. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells. Eur J Cancer 2000; 36: 1863-8.
13. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-62.
14. zur Hansen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92: 690-8.
15. Ashcroft M, Vousden KH. Regulation of p53 stability. Oncogene 1999; 18: 7637-43.
16. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36.
17. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 2001; 98: 1218-23.
18. Thomas M, Matlashewski G, Pim D, Banks L. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 1996; 18: 13265-73.
19. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner E, Wolff B, Yoshida M, Horinouti S. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999; 96: 9112-7.
20. Hietanen S, Lain S, Krausz E, Blattner C, Lane DP. Activation of p53 in cervical carcinoma cells by small molecules. Proc Natl Acad Sci USA 2000; 97: 8501-6.
21. Butz K, Whitaker N, Denk C, Ullmann A, Geisen C, Hoppe-Seyler F. Induction of the p53-target gene GADD45 in HPV-positive cancer cells. Oncogene 1999; 18: 2381-6.
22. Xirodimas DP, Stephen CW, Lane DP. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res 2001; 270: 66-77.
23. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998; 18: 7288-93.
24. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-62.
25. Jonathan J, Herod O, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian cancer. Cancer Res 1996; 56: 2178-84.